GT Biopharma announces elimination of HIV infected cells using TriKEs in preclinical test
GT Biopharma announced its Tri-Specific Killer Engager can target HIV infected cells in University of Minnesota's preclinical testing. The data demonstrate that a (BiKE) construct containing the Fab of an HIV bnAb and an anti-CD16 component can eliminate HIV-infected targets that express the HIV. April 24, 2019